Project Grant R01HL172490
Award Date
6/17/24
Completion Date
5/31/28
Dollars Obligated
$693K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Ohio, USA
Similar Awards
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $616,000.00 to Northwestern University to conduct research on the role of mitochondrial metabolism in alveolar epithelial cell fate. The study aims to determine whether an increased mitochondrial NADH/NAD+ ratio and activation of the integrated stress response (ISR) pathway preclude normal alveolar epithelial differentiation,...
This $3,443,108 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), supports research to investigate the role of mitochondrial calcium uptake in lung epithelial regeneration following bacterial pneumonia. The project aims to elucidate how calcium-dependent metabolic changes and histone lysine demethylation regulate the gene program required for alveolar epithelial type 2 (AT2) cell...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $721,826 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Childrens Hospital Medical Center in Cincinnati, Ohio. The grant, effective June 1, 2025 through March 31, 2029, supports research to identify molecular mechanisms that regulate the function of alveolar matrix fibroblasts and their role in supporting capillary network formation during alveolar development. The project aims to elucidate how the transcription...
The federal Project Grant award R01HL171164, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports a research project to investigate the role of hypoxia-induced aberrant lactate generation and shuttling in promoting pro-fibrotic fibroblast phenotypes and lung fibrosis. The $786,147 award, with a project period from February 1, 2025 to November 30, 2028, will enable researchers at The Ohio State University to: 1)...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,061,189 to support research on immune crosstalk in lung injury and fibrosis. The key objectives are: 1) studying epithelial HB-EGF regulation of fibrosis and its interaction with myeloid cells, 2) uncovering mechanisms for impaired innate immunity against gram-positive infections...
This $762,867 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) program supports research to investigate the role of the protein cofilin-1 in mitochondrial quality control mechanisms that impact airway epithelial dysfunction in chronic bronchitis, a subtype of chronic obstructive pulmonary disease (COPD). The project aims to determine how the loss of cofilin-1 affects mitochondrial dynamics, mitophagy, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $651,019 to the Regents of the University of Michigan to conduct research on dysfunctional epithelial repair in pulmonary fibrosis. The key focus of this 4-year project is to elucidate the factors and pathways that contribute to aberrant epithelial cell states in persistent lung fibrosis, with the goal of identifying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the Cardiovascular Diseases Research program (CFDA 93.837), provides $805,845 to the Proteogenomics Research Institute for Systems Medicine to develop and test a novel lung precision drug delivery system (LPDDS) targeting lung myofibroblasts to treat lung fibrosis. The goal is to create "dual precision" bispecific therapeutics that can actively transport anti-fibrotic agents directly...
This $277,610 Project Grant awarded by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to determine the role of TP53 regulation in alveolar epithelial transitional cell state, and the contribution of alveolar epithelial transitional cell state to pulmonary fibrosis. The research aims to uncover the molecular mechanisms that regulate alveolar epithelial cell states and their impact on pulmonary fibrosis, a debilitating and terminal...
This $774,585 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports research to investigate the mechanisms underlying the emergence and functional role of inflammatory fibroblasts in pulmonary fibrosis. Key research activities include: Comparing the timing, persistence, and fate of inflammatory fibroblasts in mouse models of pulmonary fibrosis (bleomycin, silica) versus an...